Feed IQV
IQ

IQVIA

IQV · NYSE

$270.52 +0.32% (+$0.85)
1M +11.78%
Market Cap $44.4B
P/E Ratio 32.26x
Div. Yield -
ROE 21.95%

Bulios Fair Price

$198.88

26.5% downside

Current Price

$270.52

Undervalued Fair Value Overvalued

According to Bulios Fair Price, IQV is currently overvalued relative to its market price. How does it work?

Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?

Piotroski F-Score Strong
7/9
Valuation
46 /100
Fair
P/FCF 16.98x
P/E 32.26x
P/B 7.19x
Growth
53 /100
Stable
FCF growth 8.95%
EPS growth 11.08%
Book val. growth 4.10%
Profitability
64 /100
Moderate
Op. margin 13.57%
Gross margin 26.23%
FCF margin 15.39%
Quality
63 /100
Average
ROA 4.60%
ROIC 8.32%
Asset turnover 0.57x
Debt
19 /100
High
Int. coverage 3.04x
Debt/Equity 2.63x
Net debt/EBITDA 4.06x
Stability
91 /100
Stable
EPS volatility 13.74%
Beta 1.19x
Profitable years 6

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Ask StockBot about IQV
Online

About the company

IQVIA Holdings Inc. is a global company specializing in providing a broad range of healthcare information and analytical services. The company is headquartered in Durham, North Carolina. IQVIA operates in the bio-pharmaceutical and healthcare research sector, offering information and tools for pharmaceutical companies, biotechnology firms, healthcare organizations, and other entities.

Sector

Healthcare

Industry

Medical - Diagnostics & Research

CEO

Ari Bousbib

Employees

94,000

Headquarters

Durham

Upcoming events

03 NOV

Earnings

Upcoming earnings report

48d

We use essential cookies to run the website and optional analytics cookies to measure usage. See our Privacy Policy.